Watch These Stocks: Kirkland’s Inc., MDC Holdings (NYSE:MDC), Thompson Creek Metals Company (NYSE:TC), Lydall (NYSE:LDL), OncoMed Pharmaceuticals (NASDAQ:OMED)

Kirkland’s Inc. (NASDAQ:KIRK) shares decreased -3.10% in last trading session and ended the day at $14.05. KIRK Gross Margin is 39.70% and its has a return on assets of 6.20%. Kirkland’s Inc. (NASDAQ:KIRK) quarterly performance is -33.85%.

MDC Holdings Inc. (NYSE:MDC) ended the last trading day at $24.72. Company weekly volatility is calculated as 2.10% and price to cash ratio as 9.83. MDC Holdings Inc. (NYSE:MDC) showed a weekly performance of -4.70%.

Zacks Investment Research lowered shares of M.D.C. Holdings, Inc. (NYSE:MDC) from a hold rating to a sell rating in a research report released on Tuesday morning, MarketBeat reports.

On 04 January, Thompson Creek Metals Company Inc. (NYSE:TC) shares increased 1.78% and was closed at $0.21. TC EPS growth in last 5 year was -7.80%. Thompson Creek Metals Company Inc. (NYSE:TC) year to date (YTD) performance is 1.78%.

On December 18, 2015, Wendy Cassity, Vice President, General Counsel and Secretary of Thompson Creek Metals Company Inc. (NYSE:TC), provided notice of her resignation from the Company. Ms. Cassity’s employment with the Company will terminate in mid-January 2016.

Lydall, Inc. (NYSE:LDL) shares decreased -6.57% in last trading session and ended the day at $33.15. LDL Gross Margin is 22.80% and its has a return on assets of 12.50%. Lydall, Inc. (NYSE:LDL) quarterly performance is 11.65%.

David H. Williams, President of Lydall Performance Materials, a division of Lydall, Inc. (NYSE:LDL), will be departing the Company effective January 10, 2016. Mr. Williams will receive severance benefits consistent with the terms of his Agreement dated June 27, 2012, which include one year of salary, bonus, health benefits, and optional outplacement services. Receipt of these severance benefits are subject to his execution, without revocation, of a valid release in substantially the form attached to his Agreement. A copy of his Agreement was previously filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 1, 2012.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) caters to the Healthcare space. Its weekly performance is 2.52%. On the last day of trading company shares ended up at $21.97. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) distance from 50-day simple moving average (SMA50) is -24.64%.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), announced that Paul J. Hastings, Chairman and Chief Executive Officer, will present a corporate update at the 34th Annual JPMorgan Healthcare Conference in San Francisco on Thursday, January 14, 2016 at 10:00 am Pacific Time.